What was approved and why it matters
Genentech's Enspryng (satralizumab) is the first thyroid eye disease therapy that patients can inject at home, every four weeks after loading doses. It is an IL-6 receptor antibody already approved for neuromyelitis optica since 2020.
Frequently asked questions
When was Enspryng approved for thyroid eye disease?
The FDA approved Enspryng for adults with thyroid eye disease on 15 October 2026, regardless of disease severity or duration.
What are Enspryng's projected sales in TED?
Zaash Labs' base case is about USD 260 million of US net revenue in 2031 and about USD 400 million globally in 2032.
Did both Phase III trials succeed?
No. SatraGO-2 met its primary endpoint (52.9% vs 23.4%); SatraGO-1 did not (49.0% vs 31.2%).
Figures are company reported or from published sources unless marked as Zaash Labs estimates. Sources are listed in the executive summary and the full report. Market research to support business decisions; not investment advice.